RECALL-VAXTM is a method to immunize people to produce specific natural antibodies against the beta amyloid (Aß) protein before it causes irreversible damage by accumulating in the brains of Alzheimer’s patients.
Intellect Neurosciences has already received patent for this technology in Europe, Australia, New Zealand and South Africa, and corresponding patent applications are pending in Canada, China, Japan and Israel.
Intellect Neurosciences chairman and CEO Daniel Chain said this new patent from the USPTO is yet another important milestone for the company and is indicative of the type of ground breaking research we do that is aimed at discovering and developing drugs that can fundamentally transform the way Alzheimer’s disease is treated and ultimately prevent the onset of the disease.
"Intellect has two immunotherapy approaches: The more advanced of the two is the Antisenilin platform, which uses recombinant monoclonal antibodies as highly specific drugs to prevent the accumulation of soluble Aß in the brains of Alzheimer’s patients," Chain said.
"We look forward to developing drug candidates based on RECALL-VAXTM technology with the aim of ultimately testing the vaccine in human clinical trials."